“Ideal” parathyroid hormone in erythropoietin‐stimulating agents‐resistant anemia
Open Access
Abstract
Erythropoietin-stimulating agents (ESAs) have revolutionized anemia treatment in end-stage renal disease (ESRD), but ESA resistance is increasingly identified. Secondary hyperparathyroidism (SHP) is one cause of ESA resistance. We describe a patient with ESA-resistant, transfusion-dependent anemia and mild SHP with remodeling and reticulin fibrosis on bone marrow biopsy, all of which resolved with stricter SHP management. We identified 64 patients with anemia, ESRD, and bone marrow biopsy. The parathyroid hormone (PTH) range for bony remodeling was 183–16,161.9 pg/ml versus 90.8–3283 pg/ml. The PTH range for fibrotic changes was 183–2487 pg/ml versus 90.8–16,161.9 pg/ml. We found no clear PTH range predictive for bone marrow changes.Keywords
This publication has 14 references indexed in Scilit:
- Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D StudyPLOS ONE, 2016
- Mechanisms of Anemia in CKDJournal of the American Society of Nephrology, 2012
- Hyperparathyroïdie secondaire et anémie. Effets d’un calcimimétique sur le contrôle de l’anémie des hémodialysés chroniques. Étude piloteNephrologie & Therapeutique, 2011
- Erythropoiesis Stimulatory Agent- Resistant Anemia in Dialysis Patients: Review of Causes and ManagementBlood Purification, 2009
- Treatment of Secondary Hyperparathyroidism in CKD Patients with Cinacalcet and/or Vitamin D DerivativesClinical Journal of the American Society of Nephrology, 2009
- Red Blood Cell Osmotic Fragility in Chronically Hemodialyzed PatientsNephron, 1997
- Effect of Serum Parathyroid Hormone and Bone Marrow Fibrosis on the Response to Erythropoietin in UremiaNew England Journal of Medicine, 1993
- Effect of Parathyroidectomy on Anemia in Chronic Renal FailureArchives of internal medicine (1960), 1979
- 1,25-DihydroxycholecalciferolArchives of internal medicine (1960), 1974
- 1,25-dihydroxycholecalciferol. Effect on skeletal lesions and plasma parathyroid hormone levels in uremic osteodystrophyArchives of internal medicine (1960), 1974